Semaglutide is a once-weekly prescription injection for long-term weight management. It copies a gut hormone called GLP-1, which reduces appetite and slows how quickly the stomach empties. BHRT Delivered prescribes compounded semaglutide to eligible Florida adults, online or in person at our Palm Beach County clinic, from $229 per month, with regular check-ins with a Florida-licensed provider.
A body mass index (BMI) of 30 or higher, or
A BMI of 27 or higher plus a weight-related condition such as high blood pressure, high cholesterol or type 2 diabetes.
Do not take semaglutide if you:
Have had medullary thyroid cancer, or it runs in your family.
Have Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
Are pregnant, planning pregnancy or breastfeeding.
Have had a serious allergic reaction to semaglutide.
In the main clinical trial of Wegovy (STEP 1), adults without diabetes lost on average about 15% of their body weight over 68 weeks, compared with about 2% on placebo. Results vary, and some people lose less.
Weight usually returns if the medication is stopped, so treatment is generally long term.
This trial tested brand-name semaglutide. Compounded semaglutide has not been through the same trials.
We prescribe compounded semaglutide, prepared by FarmaKeio and EVEXIAS. We do not prescribe brand-name Wegovy. Compounded medications are not FDA-approved.
Free 15-minute phone consultation. We review your weight history, health conditions and medications.
Lab testing. You choose where: at our clinic, at a Quest Diagnostics location near you, or with a mobile phlebotomist who comes to your home or office.
Your plan. A Florida-licensed provider decides whether semaglutide is appropriate and writes your prescription.
Delivery. Medication ships to your Florida address.
Dose increases. Your provider sets your schedule. A typical plan starts at 0.25 mg once a week and steps up about every four weeks.
Follow-up. We retest at 90 days and at 6 months, then every 12 months. Your provider is available between tests for side effects or dose questions.
The most common side effects are nausea, diarrhea, vomiting, constipation and stomach pain. They are most likely when starting or increasing the dose and usually ease with time.
Less common but serious risks include pancreatitis, gallbladder problems, low blood sugar (mainly with insulin or sulfonylureas), kidney injury from dehydration, and worsening of diabetic eye disease. Semaglutide carries a warning about a type of thyroid tumor seen in animal studies; it is not known whether this happens in people.
Your first step is a free 15-minute phone consultation. There is no charge and no obligation.
If you decide to go ahead
Monthly membership
Compounded semaglutide starts at $229 per month, depending on your dose. That covers:
Membership is month to month. There is no minimum commitment, and you can cancel at any time.
We do not accept insurance for memberships. We accept HSA and FSA cards, and financing is available.
Obesity is a long-term condition, and most people regain weight after stopping. Your provider can discuss maintenance options.
Yes, compounded semaglutide with a prescription from a Florida-licensed provider after a proper evaluation. We treat adults who live in Florida.
Tell us. We treat patients with type 2 diabetes and manage their medications. Semaglutide lowers blood sugar, so your provider will decide whether it is appropriate alongside your other treatment.
No. Ozempic and Wegovy are brand-name products that contain semaglutide. We prescribe compounded semaglutide, which is prepared by a compounding pharmacy.
No. Membership is month to month, with no minimum commitment. You can cancel at any time.
Then we will tell you so, and we will not prescribe treatment you don’t need.
Wegovy (semaglutide) prescribing information. Novo Nordisk / FDA.
Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). NEJM, 2021.
Lincoff AM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT). NEJM, 2023.
Aronne LJ, et al. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity (SURMOUNT-5). NEJM, 2025.
